Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | CHAT | P28329 | 1/20 | 0.61 |
| ▸ | BLVRB | P30043 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | GNG2 | P59768 | 1/20 | 0.59 |
| ▸ | GNB1 | P62873 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29486978 | 1.00 | MEN1 (0.61) | MEN1KMT2ATDP1RECQLBLM | |
| SCHEMBL3624632 | 0.93 | GNG2 (0.65) | MEN1KMT2ATDP1RECQLBLM | |
| SCHEMBL28626002 | 0.88 | FTO (0.70) | MEN1KMT2ATDP1RECQLBLM | |
| SCHEMBL5886188 | 0.87 | MEN1 (0.58) | MEN1KMT2ATDP1RECQLBLM | |
| SCHEMBL31105807 | 0.84 | MEN1 (0.55) | MEN1KMT2ATDP1RECQLBLM | |
| SCHEMBL122505 | 0.84 | MEN1 (0.55) | MEN1KMT2ATDP1RECQLBLM | |
| SCHEMBL203192 | 0.83 | GNG2 (0.43) | MEN1KMT2ATDP1RECQLBLM | |
| SCHEMBL6823049 | 0.83 | RECQL (0.43) | MEN1KMT2ATDP1RECQLBLM | |
| SCHEMBL498536 | 0.81 | GNG2 (0.74) | MEN1KMT2ATDP1RECQLBLM | |
| SCHEMBL29740272 | 0.81 | GNG2 (0.74) | MEN1KMT2ATDP1RECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132218-A1 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN HER-2 | A & G PHARMACEUTICAL INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20250154237-A1 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN PROGRANULIN | A & G PHARMACEUTICAL, INC. | 2025-05-15 | — | — | US | claimed |
| EP-4524568-A2 | METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS | Astellas Institute for Regenerative Medicine (US) | 2025-03-19 | — | — | EP | claimed |
| EP-4482861-A2 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN PROGRANULIN | A & G Pharmaceutical, Inc. (US) | 2025-01-01 | — | — | EP | claimed |
| EP-3875599-B1 | METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS | ASTELLAS INST FOR REGENERATIVE MEDICINE (US) | 2024-12-11 | — | — | EP | claimed |
| WO-2024081905-A2 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN HER-2 | A & G PHARMACEUTICAL, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| US-11779896-B2 | Magnetic-optical composite nanostructure | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2023-10-10 | — | — | US | claimed |
| US-20230310285-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | L'OREAL (FR) | 2023-10-05 | — | — | US | claimed |
| WO-2023192788-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | L'OREAL (FR) | 2023-10-05 | — | — | WO | claimed |
| WO-2023164581-A2 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN PROGRANULIN | A & G PHARMACEUTICAL, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| EP-1292298-A1 | INTRACORPOREAL MEDICAMENTS FOR HIGH ENERGY PHOTOTHERAPEUTIC TREATMENT OF DISEASE | Photogen, Inc. (US) | 2003-03-19 | — | — | EP | claimed |
| EP-1284727-A1 | INTRACORPOREAL MEDICAMENTS FOR PHOTODYNAMIC TREATMENT OF DISEASE | Photogen, Inc. (US) | 2003-02-26 | — | — | EP | claimed |
| US-20020161035-A1 | Medicaments for chemotherapeutic treatment of disease | PHOTOGEN, INC. | 2002-10-31 | — | — | US | claimed |
| EP-1210078-A1 | IMPROVED TOPICAL MEDICAMENTS AND METHODS FOR PHOTODYNAMIC TREATMENT OF DISEASE | Photogen, Inc. (US) | 2002-06-05 | — | — | EP | claimed |
| WO-2002005812-A1 | MEDICAMENTS FOR CHEMOTHERAPEUTIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| US-20020001567-A1 | Intracorporeal medicaments for high energy phototherapeutic treatment of disease | PHOTOGEN, INC. | 2002-01-03 | — | — | US | claimed |
| WO-2001076595-A1 | INTRACORPOREAL MEDICAMENTS FOR HIGH ENERGY PHOTOTHERAPEUTIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001072301-A1 | INTRACORPOREAL MEDICAMENTS FOR PHOTODYNAMIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2001-10-04 | — | — | WO | claimed |
| US-20010022970-A1 | Intracorporeal medicaments for photodynamic treatment of disease | PHOTOGEN, INC. | 2001-09-20 | — | — | US | claimed |
| WO-2001012181-A1 | IMPROVED TOPICAL MEDICAMENTS AND METHODS FOR PHOTODYNAMIC TREATMENT OF DISEASE | PHOTOGEN, INC. (US) | 2001-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132218-A1 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN HER-2 | IGSF11, IGLV6-57, FCGR2A | MEN1 3831/4885KMT2A 1769/4885TDP1 2414/4885 |
| US-20230310285-A1 | DEVELOPER COMPOSITION COMPRISING DIRECT DYE | TYR, CYB5R3, POLR1C | MEN1 2132/4885KMT2A 1128/4885TDP1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.